You are here

The Alentis start-up is taking off

April 2019

Prof. Baumert is the principal founder of ALENTIS Therapeutics, a Swiss-French biotech company developing novel therapeutics in advanced liver disease and cancer, after securing Series A financing of 11.1 M€. This company will translate the novel approaches and therapeutic compounds developed in our institute into clinical drug candidates, with the aim of improving the very poor outcomes of patients with advanced liver disease.

Continue reading